Preoperative Chemotherapy for Highly Advanced Gastric Cancer.
- Author:
Oh JEONG
1
;
Byung Sik KIM
;
Jung Hwan YOOK
;
Ji Eun CHOI
;
Kab Jung KIM
;
Sung Tae OH
Author Information
1. Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. stoh@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Stomach neoplasms;
Neoadjuvant therapy;
Prognosis
- MeSH:
Capecitabine;
Chemotherapy, Adjuvant;
Drug Therapy*;
Humans;
Korea;
Medical Records;
Mortality;
Multivariate Analysis;
Neoadjuvant Therapy;
Neoplasm Metastasis;
Prognosis;
Recurrence;
Retrospective Studies;
Stomach Neoplasms*;
Survival Rate
- From:Journal of the Korean Surgical Society
2007;73(4):302-308
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The prognosis of advanced gastric cancer is still dismal despite of aggressive surgical treatment. Many investigational approaches such as the use of adjuvant chemotherapy and neoadjuvant chemotherapy with or without radiation therapy have been widely attempted for highly advanced gastric cancer. There are, however, few studies about the use of these types of treatment in Korea. METHODS: Between 2001 and 2004, 38 patients with highly advanced gastric cancer underwent preoperative chemotherapy using the DXP (Docetaxel, Xeloda, and Cisplatin) regimen before surgery. An retrospective analysis including clinicopathological features, recurrence, and survival was performed using patient medical records. RESULTS: Twenty-five patients had locally advanced gastric cancer without a distant metastasis, and 13 patients had a distant metastasis or peritoneal metastasis. Patients received the chemotherapy regimen an average of 4.2 times. A partial response and stable disease were found in 28 (73.7%) and 10 (26.3%) patients, respectively, according to the RECIST criteria. Twenty- one (84%) of 25 patients without a distant metastasis had a curative resection compared to 6 (46.2%) of 13 patients with a distant metastasis (P=0.024). Four patients (10.5%) had complications with 1 postoperative death. The overall 5 year survival rate was 34% and the median survival duration was 22 months (49%, 34 months for the locally advanced group vs. 0%, 10 months for the distant metastasis group; P<0.001). The only predictor of prognosis of patients as determined by multivariate analysis was the pathological TNM stage. CONCLUSION: Preoperative chemotherapy can be safely performed without increased postoperative morbidity and mortality. To define the actual benefits for patient survival after pre-operative chemotherapy, a large scale randomized prospective control study should be performed.
